semaglutide sustained release (PT403) / Peptron - LARVOL DELTA

Peptron secures Australian patent for long-acting semaglutide injection (Korea Biomedical Review) - "Peptron...that it has secured a patent in Australia for a long-acting injectable formulation of semaglutide, designed to last over one month....The patent covers PT403, the company’s diabetes and obesity treatment candidate, which is based on semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist....The patent ensures Peptron’s exclusive rights to PT403 and similar formulations in Australia until June 22, 2042."

Patent • Diabetes • Metabolic Disorders • Obesity